^
Association details:
| Biomarker: | TP53 mutation + PIK3CA mutation + CD74 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
Published date:
06/24/2021
Excerpt:
A 70-year-old man with a 20-year history of smoking...diagnosed with undifferentiated large-cell lung cancer of the left lung...Next generation sequencing (NGS, Geneseeq Technology Inc) found mutations in TP53, PIK3CA, and CD74...we administered oral antiangiogenic therapy with anlotinib (12 mg/d)....At the last follow-up, the patient’s PFS and overall survival (OS) were 21.5 and 27.5 months, respectively, after anlotinib treatment.
DOI:
10.3389/fonc.2021.680818
